BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Berlin, Germany, Cambridge, MA, USA, August 28, 2023 – Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01…
Read More